Trem2 Microglia Pathway In Alzheimer'S Disease represents a key pathological mechanism in neurodegenerative diseases. This page explores the molecular and cellular processes involved, their contribution to disease progression, and therapeutic implications.
Triggering receptor expressed on myeloid cells 2 (TREM2) is a cell surface receptor primarily expressed on microglia in the central nervous system. Rare coding variants in TREM2 (including R47H, R62H, D87N, and Y38C) increase Alzheimer's disease (AD) risk by approximately 2-4 fold, similar to the effect of one APOE ε4 allele. This page details the biology of TREM2, its role in microglial function, disease-associated microglia (DAM) activation, and therapeutic targeting strategies.
¶ Gene and Protein Structure
The TREM2 gene (located on chromosome 6p21.1) encodes a type I transmembrane protein with: [Wang et al., TREM2 mediates microglial phagocytosis (2015)]
- Extracellular Ig-like V-type domain (ligand binding)
- Single transmembrane helix
- Cytoplasmic tail with ITAM motif (via DAP12 adaptor)
- Highest expression in microglia within the brain
- Also expressed in peripheral macrophages, dendritic cells, and osteoclasts
- Upregulated in AD brain, particularly around amyloid plaques
flowchart TD
ATREM ["2 Ligand Binding"] --> BTREM ["2 Dimerization"]
B --> C["ITAM Phosphorylation by SRC"]
C --> D["SYK Recruitment"]
D --> E{"Signaling Cascade"}
E --> F["PI3K/AKT Pathway"]
E --> G["MAPK/ERK Pathway"]
E --> HNF-κB P["athway"]
E --> I["Calcium Signaling"]
F --> J["Cell Survival, Proliferation"]
G --> K["Gene Transcription"]
H --> L["Inflammatory Response"]
I --> M["Phagocytic Activity"]
- PI3K/AKT: Cell survival, metabolic regulation
- MAPK/ERK: Gene transcription, cell proliferation
- NF-κB: Inflammatory gene expression
- Calcium mobilization: Cytoskeletal reorganization, phagocytosis
¶ TREM2 Ligands
¶ Identified Ligands
- Apolipoproteins: APOE, APOJ/clusterin
- Lipids: Phospholipids, sulfatides, gangliosides
- Aβ: Amyloid-beta oligomers and fibrils
- Tau: Phosphorylated tau species
- Bacterial components: Lipopolysaccharide (LPS)
¶ Ligand Recognition
TREM2 recognizes lipid components and protein aggregates, enabling microglia to sense: [Ulrich et al., TREM2 in neurodegeneration (2017)]
- Myelin debris (in demyelinating diseases)
- Amyloid plaques (in AD)
- Apoptotic cells
TREM2 is critical for microglial phagocytosis of: [Zhou et al., TREM2 and Aβ clearance (2020)]
- Aβ plaques
- Apoptotic neurons
- Myelin debris
- Cellular waste
TREM2 signaling drives metabolic changes: [Keren-Shaul et al., DAM cells (2017)]
- Increased glycolysis
- Lipid metabolism activation
- Mitochondrial function support
¶ Survival and Proliferation
TREM2 provides trophic support: [Gratuze et al., TREM2 and neurodegeneration (2018)]
- Reduces apoptosis
- Supports microglial survival
- Enhances process motility
flowchart TD
A["Homeostatic Microglia"] --> B["Intermediate DAM"]
B --> C["Fully Activated DAM"]
A -->|"TREM2-independent"| B
B -->|"TREM2-dependent"| C
C --> D["Phagocytic"]
C --> E["Inflammatory"]
C --> F["Metabolically Active"]
D --> G["Plaque Clearance"]
E --> H["Cytokine Release"]
F --> I["Lipid Metabolism"]
TREM2-dependent DAM express: [Colonna and Wang, TREM2 in AD (2016)]
- Upregulated: APOE, CD74, LPL, CTSD, HEXB, TREM2
- Downregulated: homeostatic genes (P2RY12, TMEM119)
- DAM form around amyloid plaques ("plaque-associated microglia")
- Initially protective (Aβ clearance)
- May become dysregulated in later stages
¶ TREM2 Variants and AD Risk
| Variant | Risk (OR) | Effect on Function | [Song et al., CD33 in AD (2018)]
|---------|-----------|-------------------| [Xiang et al., TREM2 variants (2020)]
| R47H | ~2.5 | Strongly reduced ligand binding | [Schlepckow et al., TREM2 R47H (2020)]
| R62H | ~2.0 | Reduced ligand binding | [Lee et al., TREM2 function (2021)]
| D87N | ~1.5 | Moderate functional impact | [Zhao et al., TREM2 Y38C (2018)]
| Y38C | ~3.0 | Loss of function | [Parhizkar et al., TREM2 loss (2019)]
- Impaired Aβ clearance
- Reduced microglial metabolic fitness
- Altered inflammatory response
- Defective phagocytosis
In early AD: [Jay et al., Early AD TREM2 (2017)]
- TREM2 upregulation around plaques
- DAM formation attempted
- Aβ clearance efforts
In later stages: [Song et al., TREM2 in later AD (2020)]
- TREM2 may contribute to tau spreading
- Neuroinflammation exacerbation
- Synaptic loss
TREM2 activation may be beneficial: [Filipello et al., TREM2 activation (2021)]
- Enhanced Aβ clearance
- Improved microglial function
- Reduced neuroinflammation (if properly modulated)
- AL002: Anti-TREM2 antibody (Phase 2)
- AL003: Anti-TREM2 antibody (Phase 1)
- Sintilimab: Checkpoint inhibitor approach
- Antibody-mediated TREM2 clustering
- Enhanced DAP12 signaling
- DAM activation
- Balancing beneficial phagocytosis with inflammation
- Timing of intervention (early vs late AD)
- Peripheral vs central effects
- TREM2 gene therapy: AAV delivery
- Small molecule agonists: Blood-brain barrier penetrant
- Decoy receptors: Soluble TREM2 variants
The study of Trem2 Microglia Pathway In Alzheimer'S Disease has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development. [Li et al., Trem2 pathway (2020)]
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions. [Mathys et al., Single-cell AD (2017)]
TREM2 variants significantly influence AD risk
| Variant |
Risk (OR) |
Function |
Effect |
| R47H |
3-4x |
Ligand binding |
Loss of function |
| R62H |
2-3x |
Ligand binding |
Partial loss |
| D87N |
1.5-2x |
Processing |
Intermediate |
| H157Y |
2x |
Signaling |
Partial loss |
| T96K |
2x |
Unknown |
Reduced function |
The R47H variant (rs75932628)- Increased AD risk: 3-4 fold
- Mechanism: Impaired lipid sensing
- Function: Reduced phagocytosis of Aβ
The R62H variant (rs143332484):
- Higher population frequency: ~1%
- Moderate AD risk: 2-3 fold
- Similar mechanism: Ligand binding defect
- Partial loss of function
- R62H is not fully loss-of-function
- Some variants may be protective (rare)
- TREM2 haploinsufficiency may have benefits
¶ Activating Ligands
TREM2 recognizes multiple ligands| Ligand | Source | Function |
|--------|--------|---| Lipids | Apolipoproteins (ApoE, ApoJ) | Cholesterol sensing |
| Aβ | Amyloid plaques | Phagocytosis |
| Lipoteichoic acid | Bacteria | Immune response |
| Phospholipids | Apoptotic cells | Clearance |
| HS/HSPG | Extracellular matrix | Cell debris |
flowchart TD
A["TREM2 Ligand Binding"] --> B["DAP12 Recruitment"]
B --> C["SRC Kinase Phosphorylation"]
C --> D["SYK Activation"]
D --> E["PI3K/Akt Pathway"]
D --> F["MAPK/ERK Pathway"]
D --> G["PLCG2 Pathway"]
E --> H["Microglial Survival"]
F --> I["Cytokine Production"]
G --> J["Phagocytosis"]
H --> K["Neuroprotection"]
J --> K
- PI3K/Akt: Survival, proliferation
- MAPK/ERK: Gene expression, cytokine production
- NF-κB: Inflammatory response
- mTORC1: Metabolic regulation
- PLCγ2: Calcium signaling, phagocytosis
TREM2 drives specific microglial programs- Stage 2 DAM: Phagocytic, lysosomal genes
- Functions: Aβ clearance, tissue repair
- Pro-inflammatory: IL-1β, TNF-α production
- Chronic activation: May be detrimental
- Role in progression: Worsens pathology
| Stage |
TREM2 Effect |
Outcome |
| Preclinical |
Protective |
Aβ clearance |
| Early AD |
Compensatory |
Slows progression |
| Mid AD |
Insufficient |
Plaque accumulation |
| Late AD |
Dysregulated |
Chronic inflammation |
¶ Cholesterol and TREM2
TREM2 senses cholesterol metabolites- *- Function: Links metabolism to immunity
- TREM2 R47H: Impaired lipid sensing
- Consequence: Reduced Aβ phagocytosis
- Therapeutic target: Enhance lipid sensing
- TREM2 agonists: Enhance function
- Lipid-based approaches: Support TREM2
- ApoE modulation: Indirect TREM2 activation
| Antibody |
Company |
Stage |
Target |
| Gosuranemab (BI 12339017) |
Roche/Genentech |
Phase 2 |
TREM2 |
| AL002a |
Alector/AbbVie |
Phase 2 |
TREM2 |
| PYC-003 |
PYC Therapeutics |
Preclinical |
TREM2 |
- Mechanism: Agonistic anti-TREM2 antibody
- Target: Enhance microglial function
- Trial: NCT04670782 (Phase 2)
- Status: Completed, results pending
- Company: Alector/AbbVie
- Mechanism: TREM2 agonist
- Trial: NCT05538530
- Rationale: Enhance TREM2 function
- Timing: Must be early in disease
- Dosing: Balance agonism vs. inflammation
- Biomarkers: Need to verify target engagement
- Selection: Enrich for TREM2 variant carriers
sTREM2 is generated by shedding- - **Levels
- **CSF sTREM- Predictive value: Associated with progression
- Therapeutic monitoring: Target engagement
- ** Lewy body pathology**: TREM2 ligands present
- Genetic association: Less strong than AD
- Microglial activation: Similar mechanisms
- TREM2 in microglia: Activated in ALS
- Genetic variants: Some association
- Therapeutic target: Microglial modulation
- TREM2 expression: In microglia
- Genetic studies: Some association
- Mechanistic overlap: With AD
- Monoclonal antibodies: Direct TREM2 activation
- Small molecules: TREM2-targeted
- Gene therapy: Enhance expression
- ApoE modulation: Indirect TREM2 activation
- Lipid supplementation: Support function
- Downstream signaling: SYK, PI3K modulators
- Anti-Aβ + TREM2: Synergistic potential
- Anti-tau + TREM2: Multi-target
- Metabolic support: Integrated approach
- TREM2 Microglial Signaling Pathway
- sTREM2 Biomarker
- Microglia in Alzheimer's Disease
- Alzheimer's Disease
- TREM2-Expressing Microglia